Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Nuvo Pharmaceuticals Inc NRIFF


Primary Symbol: MRVFF

Healthcare Drug Manufacturers - Specialty & Generic
Nuvo Pharmaceuticals Inc is a Canadian focused healthcare company doing business as Miravo Healthcare with global reach and a diversified portfolio of commercial products. Its product targets several therapeutic areas, including pain, allergy, and dermatology. The company's strategy is to in-license and acquire growth-oriented, complementary products for Canadian and international markets.


OTCQX:MRVFF - Post by User

Nuvo Pharmaceuticals Inc
Bullboard Posts
User Avatar Image
(36)
•••
Comment by miningfundion Dec 30, 2014 8:45pm
349 Views
Post# 23274136

RE:RE:RE:RE:RE:When to sell the company?

RE:RE:RE:RE:RE:When to sell the company?The matter of FDA approvals seems extremely complex! In its MDA of 11/10/2014, management advised that approval of WF10 would take a number of years? "Regardless of the future development plans for WF10, a number of additional studies will need to be conducted before WF10 can be submitted for regulatory approval for the treatment of allergic rhinitis or any other illness and there can be no assurance that the results of these additional studies will be favourable or that regulators will approve WF10 for these or other purposes. Any such studies and approvals would be expected to take a number of years."
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities